Preservation of visual acuity · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes preservation of visual acuity compared with standard treatment alone (very low certainty).
1 finding from 1 review
Severity of pain on day 3 · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes severity of pain on day 3 compared with standard treatment alone (very low certainty).
1 finding from 1 review
Duration of time requiring intravenous antibiotics · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes duration of time requiring intravenous antibiotics compared with standard treatment alone (very low certainty).
1 finding from 1 review
Surgical intervention · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes need for surgical intervention compared with standard treatment alone (very low certainty).
1 finding from 1 review
Adverse effects: exposure keratopathy · patients age 10 years and older with periorbital or orbital cellulitis
It is very uncertain whether standard treatment plus systemic corticosteroids changes adverse effects: exposure keratopathy compared with standard treatment alone (very low certainty).
1 finding from 1 review
Return visit to health care (not reported) · patients age 10 years and older with periorbital or orbital cellulitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality Mortality at latest · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) leads to lower mortality at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Bronchopulmonary dysplasia/chronic lung disease · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) probably leads to lower mortality or BPD at 36 weeks' PMA compared with control (placebo or nothing) (moderate certainty).
1 finding from 1 review
Cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Death or cerebral palsy · preterm infants with chronic lung disease
Systemic corticosteroids (dexamethasone or hydrocortisone) showed no clear difference in mortality or cerebral palsy ‐ at latest reported age compared with control (placebo or nothing) (high certainty).
1 finding from 1 review
Change in hearing threshold determined by PTA Range 0 dB to 140 dB Negative values represent lowering and positive values represent raising of the hearing threshold. A lower hearing threshold represents hearing improvement. Â · sudden sensorineural hearing loss
Intratympanic plus systemic corticosteroids (combined therapy) showed no clear difference in change in hearing threshold determined by PTA Range 0 dB to 140 dB… compared with systemic corticosteroids alone (low certainty).
2 findings from 1 review
Proportion of patients whose hearing is improved · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes proportion of patients whose hearing is improved compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Final hearing threshold determined by PTA (a lower value represents better hearing) · sudden sensorineural hearing loss
It is very uncertain whether intratympanic plus systemic corticosteroids (combined therapy) changes final hearing threshold determined by PTA A lower value represents… compared with systemic corticosteroids alone (very low certainty).
2 findings from 1 review
Adverse eventsb · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Persistent tympanic membrane perforation · sudden sensorineural hearing loss
2 findings from 1 review
Vertigo/dizziness: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Vertigo/dizziness: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review
Ear pain: timing not reported · sudden sensorineural hearing loss
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Ear pain: at the time of injection · sudden sensorineural hearing loss
2 findings from 1 review